GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Egetis Therapeutics AB (OSTO:EGTX) » Definitions » Debt-to-Equity

Egetis Therapeutics AB (OSTO:EGTX) Debt-to-Equity : 0.23 (As of Mar. 2025)


View and export this data going back to 2011. Start your Free Trial

What is Egetis Therapeutics AB Debt-to-Equity?

Egetis Therapeutics AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was kr29.20 Mil. Egetis Therapeutics AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was kr69.50 Mil. Egetis Therapeutics AB's Total Stockholders Equity for the quarter that ended in Mar. 2025 was kr433.30 Mil. Egetis Therapeutics AB's debt to equity for the quarter that ended in Mar. 2025 was 0.23.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Egetis Therapeutics AB's Debt-to-Equity or its related term are showing as below:

OSTO:EGTX' s Debt-to-Equity Range Over the Past 10 Years
Min: 0   Med: 0.01   Max: 0.35
Current: 0.23

During the past 13 years, the highest Debt-to-Equity Ratio of Egetis Therapeutics AB was 0.35. The lowest was 0.00. And the median was 0.01.

OSTO:EGTX's Debt-to-Equity is ranked worse than
58.68% of 1014 companies
in the Biotechnology industry
Industry Median: 0.14 vs OSTO:EGTX: 0.23

Egetis Therapeutics AB Debt-to-Equity Historical Data

The historical data trend for Egetis Therapeutics AB's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Egetis Therapeutics AB Debt-to-Equity Chart

Egetis Therapeutics AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.01 0.01 0.21 0.24

Egetis Therapeutics AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.25 0.27 0.35 0.24 0.23

Competitive Comparison of Egetis Therapeutics AB's Debt-to-Equity

For the Biotechnology subindustry, Egetis Therapeutics AB's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Egetis Therapeutics AB's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Egetis Therapeutics AB's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Egetis Therapeutics AB's Debt-to-Equity falls into.


;
;

Egetis Therapeutics AB Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Egetis Therapeutics AB's Debt to Equity Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Egetis Therapeutics AB's Debt to Equity Ratio for the quarter that ended in Mar. 2025 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Egetis Therapeutics AB  (OSTO:EGTX) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Egetis Therapeutics AB Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Egetis Therapeutics AB's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Egetis Therapeutics AB Business Description

Traded in Other Exchanges
Address
Grev Turegatan 11 C, Stockholm, SWE, 114 46
Egetis Therapeutics AB is an integrated pharmaceutical drug development company, focusing on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment.

Egetis Therapeutics AB Headlines

No Headlines